Case report: Intermediate uveitis caused by black ink tattoo
July 24, 2021
Jonathan D. Shader, DO, CPA, presents a case study involving an uncommon cause of posterior-intermediate uveitis: the black ink used to create a tattoo.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Ocular Surface Disease
Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
July 26, 2021
Elizabeth Yeu, MD, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of TP03 for the treatment of patients diagnosed with Demodex blepharitis.
Dry Eye Flares: An Overview
June 30, 2021
Cynthia Matossian, MD, FACS, provides an overview on dry eye flares, including causes, symptoms, and her experience with dry eye flare patients.
Pulling back the curtain on racial inequities in ocular health care
June 29, 2021
AAO develops task forces to evaluate academy, review outcomes in ophthalmology.
Santen earns FDA approval for cyclosporine ophthalmic emulsion eye drops to treat vernal keratoconjunctivitis
June 25, 2021
Santen Inc. announced Thursday that the U.S. FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops to treat vernal keratoconjunctivitis (VKC).
Disparities in dry eye severity, access to dry eye care in racial and ethnic minorities
June 25, 2021
Patients who are members of racial and ethnic minority groups present clinically with worse objective measures of dry eye than patients who do not belong to these groups, new research shows.
Smartphone screening and referral increases access to care for people with eye problems
June 22, 2021
According to investigators, the system has been shown to almost triple the number of people with eye problems attending primary care, as well as increasing appropriate uptake of hospital services.
Artificial cornea implantation: High postop infectious keratitis rate
June 22, 2021
Postop management with long-term topical antibiotics is critical to successful device retention.
Oyster Point Pharma enrolls first subject in phase 2 clinical trial of OC-01 nasal spray for neurotrophic keratopathy
June 21, 2021
Oyster Point Pharma announced today the enrollment of the first participant in its OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray to treat stage 1 neurotrophic keratopathy (NK).
ASCRS 2021 going live
June 17, 2021
The event, being held at the Mandalay Bay Resort and Casino in Las Vegas, is offering a full agenda for in-person attendees.